• Giuseppe Tridente


Muromonab (muromonab-CD3, orthoclone-OKT3), is the first monoclonal antibody commercialized for human therapy. It was initially approved by FDA in 1986, and subsequently almost everywhere, but was discontinued in 2010 due to the availability of other treatments with similar efficacy and fewer side effects, and consequent declining sales. OKT3 is a fully murine IgG2a directed to the T3 antigen (CD3) expressed on human T cells. It was indicated and largely used to control acute allograft rejection in renal, cardiac and hepatic transplant patients.


Aseptic Meningitis Temporal Arteritis Acute Allograft Rejection Cytokine Release Syndrome Human Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Smith LS (1996) Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coordination 6:109–121Google Scholar
  2. 2.
    ORTHOCLONE® (muromonab-CD3) Product Information Janssen-Cilag, 1992Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations